Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review
Эволюция подходов к производству рекомбинантных белков в фармацевтической промышленности: критический обзор
2024-01-31
SCID: 54.1/kfmmg567
Discuss with AI
metabolic engineeringrecombinant biopharmaceuticalsrecombinant protein productionsynthetic biologyupstream and downstream processing
Figures from the paper
Abstract (AI)
Many beneficial proteins have limited natural availability, which often restricts their supply and thereby reduces their potential for therapeutic or industrial usage. The advent of recombinant DNA (rDNA) technology enables the utilization of different microbes as surrogate hosts to facilitate the production of these proteins. This microbial technology continues to evolve and integrate with modern innovations to develop more effective approaches for increasing the production of recombinant biopharmaceuticals. These strategies encompass fermentation technology, metabolic engineering, the deployment of strong promoters, novel vector elements such as inducers and enhancers, protein tags, secretion signals, synthetic biology, high-throughput devices for cloning, and process screening. This appraisal commences with a general overview regarding the manufacture of recombinant proteins by microbes and the production of biopharmaceuticals, their trends towards the development of biopharmaceuticals, and then discusses the approaches adopted for accomplishing this. The design of the upstream process, which also involves host selection, vector design, and promoter design, is a crucial component of production strategies. On the other hand, the downstream process focuses on extraction and purification techniques. Additionally, the review covers the most modern tools and resources, methods for overcoming low expression, the cost of producing biopharmaceuticals in microbes, and readily available recombinant protein products.
Key Findings
1
Downstream processing emphasizes extraction and purification strategies, while modern reviews address tools for cloning, screening, and overcoming low expression.
2
Microbial biopharmaceutical manufacturing is evaluated in terms of production costs and commercially available recombinant protein products.
3
Recombinant DNA technology enables microbial surrogate hosts to produce therapeutically and industrially valuable proteins with limited natural availability.
4
Recombinant biopharmaceutical production has advanced through fermentation optimization, metabolic engineering, strong promoters, engineered vectors, protein tags, secretion signals, and synthetic biology.
5
Upstream process design—including host, vector, and promoter selection—is identified as crucial for improving recombinant protein production.
Research Object
Microbial production systems for recombinant biopharmaceutical proteins
Research Subject
Production strategies and process approaches for improving recombinant protein yield, expression, extraction, purification, and manufacturing efficiency
Publication Details
Publication Date
2024-01-31
Journal
Publisher
ISSN
Cited by
65
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Once-Weekly Semaglutide in Adults with Overweight or Obesity2021
Recombinant protein expression in Escherichia coli: advances and challenges2014
Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development2019
Secretory expression of recombinant small laccase genes in Gram-positive bacteria2023